aiwiki.page
English
Science / Biology / eosinophil

Eosinophil

A granule-containing white blood cell involved in immune defense, tissue regulation, and eosinophilic inflammatory diseases.

37 keywords7 linked from5 not yet writtenWritten by AI
LeukocyteInnate ImmunityAdaptive Immunit…Cell NucleusNeutrophilCytoskeletonMitochondrionHematopoiesisEosinophil

An eosinophil is a type of white blood cell distinguished by a usually bilobed nucleus and large cytoplasmic granules that stain orange-red with eosin. Eosinophils develop in bone marrow, circulate briefly in blood, and enter tissues, particularly the gastrointestinal tract. They belong to the innate immune system, but their development and activities are closely coordinated with adaptive immunity. In healthy adults, they commonly account for approximately 1–4% of circulating leukocytes, although reference intervals vary among laboratories and populations.

Eosinophils are best known for their association with parasitic worms, allergic disease, and certain inflammatory disorders. Their biological role is broader: they release toxic granule proteins, lipid mediators, and signaling molecules, and participate in interactions involving tissue repair, local immune responses, and barrier function. These activities can be protective or harmful depending on the tissue, stimulus, and duration of activation. Research on eosinophils has consequently shifted from viewing them principally as parasite-killing cells to examining their diverse, context-dependent functions in health and disease.

Discovery, appearance, and cellular organization

The identification of eosinophils depended on nineteenth-century advances in microscopy and differential staining. Paul Ehrlich described eosinophilic leukocytes in 1879 using their affinity for acidic dyes. Their name refers to eosin, a dye whose name derives from Eos, the Greek goddess of dawn. Eosinophilia describes staining behavior rather than cellular acidity: eosin binds strongly to positively charged components, especially the basic proteins concentrated in eosinophil granules.

A mature human eosinophil is generally about 12–17 micrometres in diameter in a blood smear. Its nucleus usually consists of two lobes joined by a thin chromatin strand, although nuclear shape varies with maturation and disease. The conspicuous granules distinguish it from a neutrophil, whose nucleus commonly has more lobes and whose granules are less intensely eosinophilic. Basophils form a separate granulocyte lineage with different granule contents and staining properties; they are not developmental stages of eosinophils.

Under electron microscopy, many mature eosinophil-specific granules contain a dense crystalline core surrounded by a less dense matrix. Major basic protein is particularly concentrated in the core, whereas eosinophil peroxidase, eosinophil cationic protein, and eosinophil-derived neurotoxin are prominent matrix constituents. This organization packages potentially damaging molecules within membrane-bound compartments. Granules can subsequently interact with an intracellular vesicular system that transports selected contents toward the cell surface.

Other cellular structures support migration and secretion. The cytoskeleton changes rapidly as an eosinophil polarizes and moves through blood-vessel walls or tissue. Membrane receptors detect chemotactic signals, growth factors, immune complexes, and environmental cues. Mitochondria, the endoplasmic reticulum, and other organelles contribute to energy metabolism, signaling, and protein processing, although mature eosinophils do not normally divide in the circulation.

Eosinophil breakdown can also produce Charcot–Leyden crystals, elongated bipyramidal structures composed predominantly of galectin-10. Such crystals occur in sputum, mucus, and tissues in several eosinophil-rich diseases. They are distinct from the crystalline cores inside intact eosinophil granules. Although historically treated mainly as evidence of eosinophil accumulation and destruction, experimental work indicates that the crystals themselves can contribute to inflammatory responses. Neither crystals nor eosinophilic staining alone identifies the cause of a disease.

Development in bone marrow and regulation of survival

Eosinophils arise through hematopoiesis from hematopoietic stem cells in bone marrow. Their developmental pathway includes progenitors progressively committed to myeloid and then eosinophil differentiation. During maturation, precursors acquire characteristic granules, condense their nuclear chromatin, and develop the receptor repertoire of mature eosinophils. Although simplified lineage diagrams often show a single linear sequence, studies of human and mouse progenitors reveal considerable heterogeneity and more complex branching relationships.

Several transcription factors help establish eosinophil identity. GATA-1, PU.1, and members of the CCAAT/enhancer-binding protein family regulate overlapping aspects of lineage commitment and maturation. Their effects depend on developmental stage, expression level, and interactions with other regulators. Eosinophil differentiation therefore reflects a coordinated program of gene expression, rather than the action of one uniquely determinative gene.

The cytokine interleukin-5, or IL-5, is especially important in promoting eosinophil production, maturation, survival, and responsiveness. Its receptor contains a specific alpha chain and a signaling beta chain shared with the receptors for IL-3 and granulocyte–macrophage colony-stimulating factor. These cytokines have overlapping effects, but IL-5 is more selective for the eosinophil lineage. Increased IL-5 signaling during certain immune responses expands marrow production and increases the supply of circulating cells. Nevertheless, IL-5 is not absolutely required for the existence of every baseline eosinophil population.

Eosinophil abundance depends on survival as well as production. In the absence of sufficient survival signals, mature cells undergo programmed cell death and can be cleared by macrophages. IL-5 and related cytokines delay this process through intracellular signaling pathways that alter the balance of survival and death proteins. Clearance of intact apoptotic cells differs biologically from disruptive cell death that spills granules and other contents into surrounding tissue.

Estimates of eosinophil lifespan vary with the experimental method and physiological setting. Blood residence is generally measured in hours, whereas tissue survival can extend for days and become substantially longer in cytokine-rich inflammatory environments. These differences help explain why a blood count is not a direct inventory of the body's eosinophils. Most eosinophils are outside the circulation, and local survival or recruitment can generate marked tissue accumulation without a proportionate rise in circulating numbers.

Circulation, tissue recruitment, and anatomical distribution

Eosinophils move between anatomical compartments through a regulated sequence of adhesion, migration, and retention. In blood, they encounter the endothelial lining of vessels; at sites producing appropriate signals, they slow, adhere firmly, and cross into tissue. Selectins participate in initial rolling interactions, while integrins support stronger attachment and migration. The eosinophil integrin α4β1 can bind vascular cell adhesion molecule 1, an interaction particularly relevant to recruitment in several inflammatory settings.

Directional movement is controlled by chemokines, small signaling proteins that establish spatial cues. The eotaxin family—CCL11, CCL24, and CCL26 in humans—acts principally through the receptor CCR3, which is strongly expressed on eosinophils. Chemokines do not act independently of vascular and tissue conditions: adhesion-molecule expression, local cytokines, extracellular matrix, and eosinophil activation state jointly determine whether cells enter and remain at a site.

Healthy eosinophils are especially prominent in the gastrointestinal lamina propria, where their density varies by anatomical region. They are normally present in much of the digestive tract distal to the esophagus. By contrast, a healthy esophageal epithelium ordinarily contains few or no eosinophils. This regional distinction is central to interpreting biopsy findings: an eosinophil density that is abnormal in one organ may overlap with physiological values in another.

Blood eosinophil numbers fluctuate with time of day and endocrine influences. They generally vary inversely with endogenous glucocorticoid activity, and administered glucocorticoids can rapidly reduce circulating counts through effects on trafficking and survival. Infection, allergic inflammation, medications, and marrow disorders can also alter the number in blood. Consequently, a single measurement captures a changing balance of production, release, redistribution, and removal rather than a fixed individual characteristic.

Circulating and tissue eosinophils can differ in surface markers, gene expression, and responsiveness. Experimental studies, especially in mice, distinguish populations associated with baseline tissue residence from those recruited during inflammation. These categories are useful but do not establish a universally accepted set of discrete human eosinophil subtypes. Tissue signals can reshape cellular behavior after arrival, and an observed population may represent a reversible activation state rather than a separate lineage. Anatomical location is therefore essential when interpreting eosinophil function.

Activation, degranulation, and inflammatory mediators

Eosinophils respond to combinations of signals rather than a single universal activating stimulus. Cytokines can prime them to respond more strongly to subsequent stimulation; chemokines direct movement and also influence activation. Other inputs include lipid mediators, complement-derived signals, and interactions with antibodies or antibody-coated targets. The expression and functional importance of individual antibody receptors vary with species and activation state, so the familiar model of an IgE-coated parasite directly activating an eosinophil does not describe every human setting.

Their granule proteins have several biochemical activities. Major basic protein can disrupt membranes and injure epithelial cells. Eosinophil cationic protein and eosinophil-derived neurotoxin belong to the ribonuclease A superfamily, although their biological actions extend beyond RNA cleavage. Eosinophil peroxidase uses hydrogen peroxide and available substrates, including halides and thiocyanate, to generate reactive oxidants. These systems can damage microorganisms or parasites, but they can also injure host tissue when released inappropriately.

Granule contents leave eosinophils through more than one mechanism. Classical exocytosis involves fusion of a granule with the plasma membrane. Compound exocytosis includes fusion between granules before discharge. Piecemeal degranulation, frequently observed in tissues, transfers selected granule contents in small vesicles without releasing an entire granule at once. Cytolysis can instead leave extracellular granules in tissue; some retain membranes and can respond to stimuli after the parent cell has disintegrated.

Eosinophils also generate mediators that are not simply prepackaged granule toxins. Cysteinyl leukotrienes contribute to airway narrowing, vascular permeability, and mucus production. Other lipid products, cytokines, and growth factors influence neighboring leukocytes, epithelial cells, nerves, and stromal cells. The resulting effects can recruit additional inflammatory cells, alter smooth-muscle activity, or promote deposition of extracellular matrix. This secretory repertoire helps explain why eosinophil-associated disease can persist beyond the moment of initial recruitment.

Extracellular traps provide another potential effector mechanism. Under particular conditions, eosinophils release extracellular DNA associated with granule proteins. Reports describe both mitochondrial DNA release without immediate cell death and nuclear chromatin release accompanying a lytic process. These mechanisms are not interchangeable, and their relative importance in human disease remains under investigation. Extracellular DNA can help entangle microorganisms, but it can also increase mucus viscosity and expose tissue to concentrated inflammatory proteins.

Parasites, infection, and type 2 immunity

Eosinophils are closely associated with type 2 immunity, a response involving cytokines such as IL-4, IL-5, and IL-13. This immune program is prominent in responses to parasitic worms and in many allergic disorders. Helper T cells and group 2 innate lymphoid cells are important sources of type 2 cytokines. Signals released by damaged or stimulated epithelial cells, including IL-25, IL-33, and thymic stromal lymphopoietin, can initiate or amplify these pathways.

Parasitic worms are often too large to be engulfed by a single immune cell. Eosinophils can instead adhere to their surfaces and release granule products and oxidants into a confined contact zone. In laboratory systems, antibodies and components of the complement system can facilitate attachment or activation. This mechanism, often discussed as antibody-dependent cellular cytotoxicity, provides a plausible means of damaging exposed larvae and other susceptible parasite stages.

The presence of eosinophils nevertheless does not establish that they are essential for parasite clearance. Experiments using eosinophil-deficient mice show outcomes that depend on parasite species, developmental stage, tissue location, and previous immune exposure. Eosinophils can contribute to protection in some models, have little measurable effect in others, or support aspects of parasite persistence by modifying the local tissue environment. Human helminth infections likewise differ greatly in their association with blood and tissue eosinophilia.

Tissue migration is particularly important. Some helminths provoke pronounced eosinophilia while larvae move through host organs, whereas organisms confined to the intestinal lumen may produce a weaker response. Protozoal infections generally do not generate the characteristic eosinophilia associated with tissue-invasive helminths. Eosinophil numbers therefore cannot be treated as a general quantitative measure of parasitic infection, and an elevated count is not specific for infection at all.

Antibacterial and antiviral activities have also been demonstrated experimentally. Eosinophils can interact with bacteria, release antimicrobial products, and in some circumstances perform phagocytosis, although they are not the principal circulating phagocytes. Eosinophil ribonucleases and other mediators have shown activity against certain viruses in experimental systems. The physiological importance of these observations varies by pathogen and model; evidence of activity in a culture dish does not by itself establish a necessary protective role in human infection.

Tissue maintenance and interactions with other cells

Eosinophils occupy tissues even in the absence of overt infection or allergy, suggesting functions beyond emergency defense. Their secreted mediators allow them to communicate with epithelial cells, fibroblasts, vascular cells, nerves, and other immune populations. These interactions can influence local immune tone, barrier integrity, and repair after injury. Much of the mechanistic evidence comes from animal experiments, and the extent to which each proposed function operates in humans remains an important distinction.

The gastrointestinal tract provides a major setting for such work. Intestinal eosinophils are positioned near the epithelial barrier and interact with the immune environment shaped by food antigens and resident microorganisms. Mouse studies implicate them in aspects of mucus-associated defenses, antibody responses, and the regulation of other leukocytes. Some reported effects differ between experimental systems, including different methods of eliminating eosinophils, indicating that their contribution depends on microbial conditions, developmental timing, and compensatory responses.

Interactions with adaptive immune cells further broaden their potential role. Activated eosinophils can express major histocompatibility complex class II molecules and costimulatory molecules, and can process or present antigens under experimental conditions. They also release mediators that affect T cells and B cells. These observations do not make eosinophils equivalent to specialized dendritic cells: their quantitative contribution to antigen presentation in normal human immune responses is less clearly established.

Eosinophils have also been investigated as contributors to metabolic regulation and tissue regeneration. In some mouse models, adipose-tissue eosinophils provide IL-4 and participate in networks involving macrophages and metabolic homeostasis. Other studies associate eosinophil-derived signals with repair responses in skeletal muscle and additional organs. Such findings identify possible biological pathways, but they do not establish that increasing eosinophils improves human metabolism or regeneration. Experimental results can depend strongly on diet, housing temperature, strain, and the type of injury.

Repair and pathology often involve the same mediators. Growth factors, including transforming growth factor beta, can support wound responses but also promote fibrosis when signaling persists. Eosinophils may influence nerves directly through granule proteins and indirectly through inflammatory mediators, altering airway responsiveness or sensory function. In cancer, eosinophil infiltration has been associated with different outcomes in different tumor types; antitumor activity and tumor-supporting effects have both been described experimentally. There is no single functional label that applies to eosinophils across all tissues.

Asthma, allergy, and organ-restricted eosinophilic disease

Eosinophils are important effector cells in many, but not all, forms of asthma. In eosinophilic airway inflammation, epithelial signals and type 2 cytokines promote marrow production, recruitment to the bronchial mucosa, and prolonged survival. Released granule proteins can injure epithelium, while lipid mediators and interactions with nerves and smooth muscle contribute to airway dysfunction. Repeated inflammation can accompany structural remodeling, including changes in extracellular matrix and the mucus-producing apparatus.

Asthma is biologically heterogeneous. Some patients have prominent eosinophilic inflammation, whereas others have predominantly neutrophilic or relatively sparse cellular inflammation. Allergic sensitization and eosinophilia overlap but are not identical: eosinophilic asthma can occur without conventional evidence of allergy. Blood eosinophil counts, sputum measurements, and fractional exhaled nitric oxide provide different kinds of information and do not measure the same process. Their usefulness as biomarkers depends on clinical context and is influenced by treatment.

In the upper airway, chronic rhinosinusitis with nasal polyps often includes type 2 inflammation and eosinophil accumulation, although inflammatory patterns vary among populations and individuals. Eosinophil products can contribute to epithelial disruption and thick secretions. Allergic rhinitis also involves eosinophils, particularly during later phases of the response, following the rapid mediator release associated with mast-cell activation. Eosinophils are therefore part of a multicellular process rather than the sole explanation for allergic symptoms.

Eosinophilic esophagitis is a chronic, immune-mediated disease characterized by symptoms of esophageal dysfunction and eosinophil-predominant inflammation. A commonly used histological threshold is at least 15 eosinophils per high-power field in an appropriate clinical setting, with consideration of other causes of esophageal eosinophilia. Interpretation requires attention to microscope field area and sampling because infiltration can be patchy. The disease can involve epithelial barrier abnormalities, food-antigen responses, and remodeling that narrows the esophagus.

Eosinophilic gastritis, enteritis, and colitis present different interpretive problems because eosinophils normally occur in those organs. Tissue location, distribution, accompanying injury, and exclusion of secondary causes are therefore important; a single universal threshold does not apply throughout the gastrointestinal tract. Eosinophilic pneumonias are another distinct group, characterized by pulmonary eosinophil accumulation in differing acute or chronic patterns. Across these disorders, finding eosinophils in a biopsy describes a cellular pattern but does not by itself determine etiology.

Blood eosinophilia, hypereosinophilic syndromes, and clonal disease

Eosinophilia is an increase in the absolute number of circulating eosinophils above the reference interval. Many laboratories use approximately 0.5×1090.5 \times 10^{9} cells per litre, equivalent to 500 cells per microlitre, as the upper boundary. The absolute eosinophil count is calculated from the total leukocyte count and the eosinophil fraction:

Absolute eosinophil count=Total leukocyte count×Eosinophil percentage100.\text{Absolute eosinophil count} = \text{Total leukocyte count} \times \frac{\text{Eosinophil percentage}}{100}.

A percentage alone can be misleading because a change in another white-cell population can alter the eosinophil percentage without increasing the absolute eosinophil number.

Conventionally, blood eosinophilia is described as mild at approximately 500–1,500 cells per microlitre, moderate at 1,500–5,000, and severe above 5,000. These categories describe counts, not a reliable scale of tissue injury. Hypereosinophilia generally refers to counts of at least 1,500 cells per microlitre, with persistence or confirmation requirements depending on the classification used; tissue hypereosinophilia can also occur. A hypereosinophilic syndrome involves eosinophilia associated with attributable organ damage rather than an elevated count alone.

Reactive eosinophilia results from external signals stimulating an otherwise nonclonal eosinophil population. Causes include allergic disease, tissue-invasive helminths, medication reactions, and cytokine production in some inflammatory or neoplastic disorders. One severe medication-associated condition is drug reaction with eosinophilia and systemic symptoms, commonly called DRESS. Eosinophilic granulomatosis with polyangiitis is a distinct systemic disorder characterized by asthma, eosinophilia, and small- to medium-vessel vasculitis; antineutrophil cytoplasmic antibodies occur in only a subset of affected people.

Clonal eosinophilia arises in the setting of a hematologic neoplasm. Some disorders involve acquired gene rearrangements encoding persistently active tyrosine kinases. The fusion gene FIP1L1::PDGFRA, identified in 2003, is a particularly important example because it connects a molecular mechanism with sensitivity to kinase inhibition. Other relevant rearrangements involve genes such as PDGFRB, FGFR1, and JAK2. In contrast, lymphocytic-variant hypereosinophilic syndromes involve abnormal T-cell populations producing eosinophil-promoting cytokines; the expanded eosinophils themselves need not be the neoplastic population.

Organ injury can affect the heart, skin, lungs, gastrointestinal tract, and nervous system. Cardiac involvement may include eosinophilic inflammation, thrombosis, and later endomyocardial fibrosis. Toxic granule products, inflammatory signaling, and interactions with coagulation pathways can all contribute. Blood counts and organ damage do not always track closely: substantial tissue disease can occur with modest circulating numbers, while some people with persistent hypereosinophilia have no attributable organ dysfunction at the time of assessment.

Experimental methods and eosinophil-targeted treatment

Routine measurement begins with an automated complete blood count and differential. Modern analyzers distinguish leukocyte populations using combinations of light scattering, fluorescence, or chemical properties. Examination of a stained blood smear provides complementary information about morphology and abnormal cells. Tissue assessment uses histology, sometimes supplemented by immunohistochemistry for eosinophil proteins. Interpretation differs between counting intact cells and detecting extracellular granule material, because extensive degranulation can leave evidence of eosinophil activity without many recognizable cells.

Flow cytometry measures surface and intracellular markers and can help characterize activation states or abnormal accompanying lymphocyte populations. Human eosinophils commonly express CCR3 and Siglec-8, among other markers, but identification generally relies on marker combinations and light-scattering properties rather than one universally exclusive antigen. Isolation itself can alter activation or survival, making handling conditions important. Sequencing and other molecular methods are particularly relevant when investigating gene rearrangements or other evidence of clonal hematologic disease.

Experimental approaches include eosinophil-deficient mouse strains, cytokine-deficient animals, antibody-mediated depletion, and culture of eosinophils from progenitors. The ΔdblGATA and PHIL mouse models have been widely used to investigate consequences of eosinophil absence. Each method has limitations: lifelong absence can permit developmental compensation, whereas acute depletion may be incomplete or affect related pathways. Human and mouse eosinophils also differ in granule-protein families and receptor expression. Conclusions are strongest when supported by complementary methods rather than one model alone.

Targeted medicines have established that eosinophils make a causal contribution to selected human diseases. Mepolizumab and reslizumab are monoclonal antibodies directed against IL-5. Benralizumab binds the IL-5 receptor alpha chain and promotes depletion of eosinophils through antibody-dependent cellular cytotoxicity. These agents have demonstrated benefits in selected patients with severe eosinophilic asthma, and individual agents have additional indications that differ by jurisdiction. Their effects are not interchangeable with those of drugs blocking IL-4 and IL-13 signaling, which act on a broader type 2 inflammatory pathway.

Clinical trials also reveal limits to interpreting eosinophil depletion as a universal solution. Lowering blood or tissue eosinophils does not invariably produce an equivalent improvement in symptoms, structural disease, or every inflammatory pathway. Trials of anti-IL-5 treatment in eosinophilic esophagitis, for example, have demonstrated a separation between histological reduction and some clinical outcomes. Conversely, the response of PDGFRA-rearranged disease to imatinib reflects inhibition of a neoplastic kinase rather than neutralization of an eosinophil cytokine. These distinctions make molecular mechanism, tissue context, and outcome selection central to evaluating eosinophil-directed interventions.